Nivolumab vs pembrolizumab for treatment of US patients with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma: a network meta …
R Pei, Y Shi, S Lv, T Dai, F Zhang, S Liu… - JAMA network …, 2021 - jamanetwork.com
Importance Nivolumab and pembrolizumab are approved for treating platinum-refractory
recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Physicians
and patients are uncertain which drug is preferable, rendering a cost-effectiveness
comparison between them necessary. Objective To evaluate the cost-effectiveness of
nivolumab vs pembrolizumab in treating platinum-refractory R/M HNSCC. Design, Setting,
and Participants Both the network meta-analysis and cost-effectiveness analysis included …
recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Physicians
and patients are uncertain which drug is preferable, rendering a cost-effectiveness
comparison between them necessary. Objective To evaluate the cost-effectiveness of
nivolumab vs pembrolizumab in treating platinum-refractory R/M HNSCC. Design, Setting,
and Participants Both the network meta-analysis and cost-effectiveness analysis included …